Entresto (Sacubitril/valsartan)

Sacubitril/valsartan, most commonly known by its brand name Entresto, is a groundbreaking medication used for the treatment of heart failure. It was developed by the Swiss multinational pharmaceutical company Novartis and received its first major approval by the U.S. Food and Drug Administration (FDA) in 2015. The drug is a combination of a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan).

Manufacturing of this complex medicine occurs globally to meet international demand, with major production facilities located in Switzerland, the United States, and Singapore. As of 2024 and beyond, the brand remains centrally owned and managed by Novartis, maintaining its position as a cornerstone of the company's cardiovascular portfolio. The intellectual property and global distribution are controlled by the Swiss parent company, often working through local subsidiaries in various regional markets.